Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.21.1
Commitments and Contingencies - Additional Information (Detail)
Jan. 15, 2021
Loss Contingencies [Line Items]  
Loss Contingency, Lawsuit Filing Date January 15, 2021
Loss Contingency, Name of Plaintiff Genfit S.A.
Loss Contingency, Allegations alleging misappropriation of trade secrets and related causes of action based on the Company’s receipt of a Genfit protocol synopsis for Genfit’s Phase 3 clinical trial of its drug candidate elafibranor in patients with primary biliary cholangitis
Loss Contingency, Actions Taken by Defendant The Company intends to defend itself vigorously. While the outcome of any litigation is inherently uncertain, based on currently available information, management does not currently believe a loss associated with this matter is probable, nor is any amount reasonably estimable